Navigation Links
LifeGen Technologies Awarded NIH Grant to Identify Biomarkers of a Calorie Restricted Diet in Adipose Tissue
Date:10/21/2010

MADISON, Wis., Oct. 21 /PRNewswire/ -- LifeGen Technologies, LLC has been awarded a Phase I Small Business Innovative Research grant from the United States National Institute on Aging. The project is focused on identifying a robust panel of genes in adipose tissue (fat) that are regulated by a calorie restricted diet. According to Dr. Jamie Barger, Director of Operations at LifeGen, the technology developed under the NIH grant will allow LifeGen to screen for compounds that have beneficial effects on adipose tissue in a manner similar to that of a calorie restricted diet.

Caloric restriction is the only dietary intervention proven to increase both maximum and average lifespan in mammals, as well delaying age-related diseases. Because caloric restriction reduces body fat and markers of inflammation related to disease, it is thought that metabolic alterations in fat may underlie many of the health benefits associated with this dietary intervention.  "Several decades of research support the concept of caloric restriction as an effective intervention in aging retardation. This research grant clearly validates the enormous potential of LifeGen's technology in discovering the next generation of anti-aging compounds, based on caloric restriction science," said LifeGen cofounder and Chief Scientific Officer Dr. Tomas A. Prolla.

ABOUT LIFEGEN TECHNOLOGIES, LLC: LifeGen was co-founded in November 2000 by Drs. Richard Weindruch and Tomas A. Prolla, professors at the University of Wisconsin-Madison and leaders in the fields of gerontology and genetics. Drs. Prolla and Weindruch were the first scientists to use DNA microarrays to measure gene activity in mammalian tissues.

LifeGen Technologies is using gene expression technology to study how the aging process is retarded by caloric restriction (CR), the only intervention proven to increase maximum lifespan and retard aging in a diverse array of species. LifeGen has licensed technology from the University of Wisconsin for the use of such "gene expression profiling" as a method to measure the progression of the aging process at the molecular level in individual organs. This technology has been used to identify several "supermarkers" of both aging and caloric restriction, which are currently being used for compound screening.

More information is available at: http://www.lifegentech.com

CONTACT:  Jamie Barger, +1-608-886-6776, Jamie.L.Barger@gmail.com


'/>"/>
SOURCE LifeGen Technologies, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
2. Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype
3. Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters
4. Reportlinker Adds US Forensic Technologies and Services Industry
5. ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial
6. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
7. Wireless Health 2010 Explores the Roles of Wireless Technologies in Clinical Services
8. Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets
9. BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium
10. RF Technologies® Names Mark Harwood New President
11. IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... 19, 2017 , ... FireflySci Inc. is a go-getter type of company that ... accounted to two main factors. The first is the amazing customer service that ... FireflySci products all around the world. , 2016 was a tremendous sales year for ...
Breaking Biology Technology:
(Date:1/12/2017)... YORK , Jan. 12, 2017  New research undertaken ... the office of the future.  1,000 participants were simply asked ... three months which we may consider standard issue.  Insights on ... of 2017 were also gathered from futurists and industry leaders ... Dr. James Canton .  Some of ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):